Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis
- 1 October 1986
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 58 (9), 673-679
- https://doi.org/10.1016/0002-9149(86)90336-x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.Circulation, 1986
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator.Cell Metabolism, 1984
- Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions.Circulation, 1984
- Inhibition of plasmin by normal and antiplasmin-depleted human plasmaThrombosis Research, 1976
- A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test)Clinica Chimica Acta; International Journal of Clinical Chemistry, 1963
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957
- Invariants in Experimental Data on Linear Kinetics and the Formulation of ModelsJournal of Applied Physics, 1956